KVUE

+ Watchlist + Portfolio

Kenvue Inc.

Regulated industry Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $17.22
52-Week Range: $14.02 – $20.13
Market Cap: $33.04B
P/E (TTM): 20.00
EPS (TTM): 0.86
Dividend Yield: 4.88%

Advanced Metrics

Price/Book: 3.13
PEG Ratio: 1.37
Return on Equity: 15.58%
Return on Assets: 6.99%
Gross Margin: 58.44%
Operating Margin: 19.42%
Profit Margin: 10.76%
Current Ratio: 1.00
Debt/Equity: 0.82
Total Debt: $8.61B
Free Cash Flow: $1.91B
Revenue Growth: 3.00%
Earnings Growth: 8.50%
Enterprise Value: $40.54B

KVUE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$14.95B	$15.44B	$15.46B	$15.12B
Cost of Revenue	$6.67B	$6.80B	$6.50B	$6.33B
Gross Profit	$8.29B	$8.64B	$8.96B	$8.79B
Selling, General & Admin	$5.63B	$6.14B	$6.33B	$6.09B
Operating Expenses	$5.60B	$6.15B	$6.33B	$6.08B
Operating Income	$2.69B	$2.49B	$2.63B	$2.71B
EBITDA	$3.28B	$3.17B	$2.47B	$2.99B
Pretax Income	$2.64B	$2.19B	$1.42B	$2.00B
Income Tax	$573.00M	$526.00M	$385.00M	$529.00M
Net Income	$2.06B	$1.66B	$1.03B	$1.47B
Diluted EPS	1.09	0.90	0.54	0.76
Diluted Shares	1.89B	1.85B	1.92B	1.92B

KVUE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.23B	$1.38B	$1.07B	$1.06B
Receivables	$2.30B	$2.64B	$2.66B	$2.81B
Inventory	$2.23B	$1.85B	$1.59B	$1.67B
Current Assets	$5.88B	$6.14B	$5.53B	$5.70B
Total Assets	$27.32B	$27.85B	$25.60B	$27.08B
Current Liabilities	$3.93B	$5.48B	$5.74B	$5.95B
Long-Term Debt	$8.93B	$7.69B	$6.94B	$6.94B
Total Debt	$116.00M	$8.43B	$8.72B	$8.67B
Total Liabilities	$7.35B	$16.64B	$15.93B	$16.31B
Retained Earnings	$0.00	$429.00M	-$93.00M	-$204.00M
Shareholders' Equity	$19.97B	$11.21B	$9.67B	$10.77B
Working Capital	$1.95B	$657.00M	-$214.00M	-$248.00M
Net Debt	$7.76B	$6.90B	$7.42B	$7.33B

KVUE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$2.52B	$3.17B	$1.77B	$2.20B
Capital Expenditure	-$375.00M	-$469.00M	-$434.00M	-$475.00M
Free Cash Flow	$2.15B	$2.70B	$1.33B	$1.72B
Depreciation & Amortisation	$644.00M	$627.00M	$622.00M	$557.00M
Stock-Based Compensation	$137.00M	$188.00M	$254.00M	$136.00M
Investing Cash Flow	-$390.00M	-$488.00M	-$425.00M	-$436.00M
Financing Cash Flow	-$1.58B	-$2.53B	-$1.56B	-$1.84B
Dividends Paid	$0.00	-$14.55B	-$1.55B	-$1.58B
Share Repurchases	$0.00	-$7.00M	-$235.00M	-$197.00M
Net Change in Cash	$552.00M	$153.00M	-$221.00M	-$76.00M

KVUE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.74B	$3.84B	$3.76B	$3.78B	$3.91B	$3.96B
Cost of Revenue	$1.57B	$1.58B	$1.54B	$1.64B	$1.61B	$1.65B
Gross Profit	$2.17B	$2.26B	$2.23B	$2.14B	$2.30B	$2.30B
Selling, General & Admin	$1.54B	$1.50B	$1.51B	$1.53B	$1.45B	$1.54B
Operating Expenses	$1.55B	$1.51B	$1.51B	$1.50B	$1.46B	$1.54B
Operating Income	$618.00M	$752.00M	$713.00M	$632.00M	$838.00M	$758.00M
EBITDA	$701.00M	$837.00M	$774.00M	$674.00M	$921.00M	$846.00M
Pretax Income	$458.00M	$588.00M	$526.00M	$427.00M	$672.00M	$598.00M
Income Tax	$136.00M	$168.00M	$128.00M	$97.00M	$198.00M	$142.00M
Net Income	$322.00M	$420.00M	$398.00M	$330.00M	$474.00M	$456.00M
Diluted EPS	0.17	0.22	0.21	0.17	0.25	0.24
Diluted Shares	1.93B	1.93B	1.92B	—	1.92B	1.92B

KVUE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.06B	$1.07B	$1.14B	$1.06B	$1.07B	$1.11B
Receivables	$2.82B	$2.86B	$2.95B	$2.81B	$2.91B	$2.93B
Inventory	$1.68B	$1.78B	$1.79B	$1.67B	$1.67B	$1.72B
Current Assets	$5.71B	$5.85B	$6.03B	$5.70B	$5.79B	$5.90B
Total Assets	$26.26B	$27.13B	$27.25B	$27.08B	$26.85B	$26.73B
Current Liabilities	$6.67B	$5.99B	$6.16B	$5.95B	$5.90B	$5.87B
Long-Term Debt	$6.20B	$7.06B	$7.06B	$6.94B	$7.07B	$7.07B
Total Debt	$8.85B	$8.74B	$9.11B	$8.67B	$8.80B	$8.61B
Total Liabilities	$16.20B	$16.40B	$16.61B	$16.31B	$16.25B	$16.18B
Retained Earnings	-$163.00M	-$136.00M	-$136.00M	-$204.00M	-$128.00M	-$70.00M
Shareholders' Equity	$10.05B	$10.73B	$10.63B	$10.77B	$10.61B	$10.55B
Working Capital	-$956.00M	-$134.00M	-$124.00M	-$248.00M	-$101.00M	$32.00M
Net Debt	$7.57B	$7.54B	$7.83B	$7.33B	$7.59B	$7.37B

KVUE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$428.00M	$621.00M	$294.00M	$854.00M	$489.00M	$688.00M
Capital Expenditure	-$179.00M	-$88.00M	-$98.00M	-$110.00M	-$139.00M	-$64.00M
Free Cash Flow	$249.00M	$533.00M	$196.00M	$744.00M	$350.00M	$624.00M
Depreciation & Amortisation	$136.00M	$142.00M	$141.00M	$138.00M	$143.00M	$145.00M
Stock-Based Compensation	$44.00M	$37.00M	$25.00M	$30.00M	$29.00M	$32.00M
Investing Cash Flow	-$167.00M	-$90.00M	-$104.00M	-$75.00M	-$167.00M	-$78.00M
Financing Cash Flow	-$310.00M	-$548.00M	-$110.00M	-$869.00M	-$295.00M	-$587.00M
Dividends Paid	-$392.00M	-$393.00M	-$398.00M	-$398.00M	-$398.00M	-$398.00M
Share Repurchases	-$63.00M	-$64.00M	-$70.00M	$0.00	$0.00	$0.00
Net Change in Cash	-$49.00M	-$17.00M	$80.00M	-$90.00M	$27.00M	$23.00M

Market Snapshot

About

Kenvue Inc. is a consumer health company formed through Johnson & Johnson's spin-off of its consumer health business. The company owns a portfolio of well-known brands including Tylenol, Listerine, Johnson's Baby, Band-Aid, Neutrogena, and Aveeno. Kenvue focuses on self-care products across skin health and beauty, essential health, and personal care categories, serving consumers in more than 100 countries worldwide.